deltatrials
Recruiting PHASE1 INTERVENTIONAL 8-arm NCT07120425

A Study of IBI3032 in Healthy Participants

A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IBI3032 in Healthy Participants

Sponsor: Fortvita Biologics (USA)Inc.

Conditions Healthy
Interventions IBI3032 placebo
Updated 2 times since 2025 Last updated: Sep 11, 2025 Started: Sep 10, 2025 Primary completion: Nov 13, 2025 Completion: Nov 13, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently actively recruiting participants. Fortvita Biologics (USA)Inc. leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshotNot Yet Recruiting~Oct 2025 – present · 9 months · monthly snapshotRecruiting

Change History

2 versions recorded

  1. Oct 2025 — Present [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  2. Sep 2025 — Oct 2025 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fortvita Biologics (USA)Inc.
Data source: Fortvita Biologics (USA)Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations